A study of the safety and efficacy of CNTO328 in combination with best supportive care compared to best supportive care in patients with Multicentric Castleman's Disease

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-012380-34

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this study is to demonstrate that CNTO 328 in combination with BSC is superior to BSC in terms of durable tumor and symptomatic response among subjects with multicentric Castleman’s disease (MCD).


Critère d'inclusion

  • Multicentric Castleman's disease